Treatment for Cannabis Withdrawal

Recognition and Diagnosis

The American Psychiatric Association suggests that cannabis withdrawal syndrome occurs in approximately 50-95% of heavy users and up to one-third of regular users in the general population, characterized by symptoms such as irritability, anxiety, insomnia, and physical symptoms after cessation of prolonged or heavy cannabis use 3, 4
The British Journal of Anaesthesia guidelines indicate that diagnosis requires three or more symptoms, including irritability or anger, insomnia, altered mood, and physical symptoms, after cessation of cannabis use 1, 2
Symptom onset occurs 24-72 hours after cessation, peaks in the first week, and typically lasts 1-2 weeks, though some symptoms may persist up to 3 weeks in heavy users 1, 2

The American College of Physicians recommends short-duration psychosocial support modeled on motivational principles as initial treatment in non-specialized settings, including brief interventions, advice on reducing or stopping cannabis consumption, supportive counseling, and follow-up monitoring 5, 6
Patients who do not respond to short-duration psychological support should be referred for specialized treatment, according to the Praxis Medical Insights guidelines 5, 6

The British Journal of Anaesthesia suggests that withdrawal should be conducted in a supportive environment with regular monitoring, using tools like the Cannabis Withdrawal Scale to assess symptom severity 1, 2, 5, 6

The British Journal of Anaesthesia guidelines recommend considering nabilone or nabiximols substitution for patients with cannabis withdrawal symptoms who consumed more than 1.5 g/day of high-THC smoked cannabis or more than 20 mg/day of THC-dominant cannabis oil 1, 2
Nabilone or nabiximols should not be used for patients consuming less than these thresholds or using cannabis products with unknown CBD/THC content less than 2-3 times per day, as per the British Journal of Anaesthesia guidelines 1, 2

The Praxis Medical Insights guidelines suggest that symptomatic medications may be used for relief of specific withdrawal symptoms, such as anxiolytics for agitation 5, 6

The British Journal of Anaesthesia guidelines indicate that patients with suspected cannabis withdrawal syndrome should be referred to psychiatry or addiction medicine providers for initiation or guidance of treatment with nabilone or nabiximols, exploration of other treatment options, and management of complicated withdrawal 1, 2, 6, 7
Inpatient admission for medically assisted withdrawal is indicated for patients with significant comorbid mental health disorders, polysubstance use, or risk of severe complications, according to the Praxis Medical Insights guidelines 4, 6

The Praxis Medical Insights guidelines explicitly contraindicate the use of dexamphetamine for treatment of cannabis use disorders or withdrawal 5, 7
The Praxis Medical Insights guidelines emphasize the importance of combining pharmacological approaches with psychosocial support for optimal outcomes 6